Organon & Co
About: Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Employees: 10,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 102
18% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $21.7M
3.02% more ownership
Funds ownership: 76.78% [Q3] → 79.8% (+3.02%) [Q4]
1% more funds holding
Funds holding: 711 [Q3] → 717 (+6) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 206 | Existing positions reduced: 237
17% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]
19% less capital invested
Capital invested by funds: $3.78B [Q3] → $3.07B (-$709M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 41%upside $15 | Equal-Weight Maintained | 9 Apr 2025 |
Barclays Balaji Prasad 16% 1-year accuracy 7 / 44 met price target | 126%upside $24 | Overweight Maintained | 14 Feb 2025 |
Financial journalist opinion
Based on 11 articles about OGN published over the past 30 days
